MTVA vs NBP

MetaVia Inc. vs NovaBridge Biosciences — Valuation Comparison 2026

MTVA

Biotechnology
MetaVia Inc.
Quality
3.7
out of 10
Value Trap
39
LOW
Price
$3.10
Last close
Models
9/13
Active
VS

NBP

Biotechnology
NovaBridge Biosciences
Quality
3.0
out of 10
Value Trap
12
SAFE
Price
$1.87
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType MTVA Fair ValueMTVA Upside NBP Fair ValueNBP Upside
Bayesian DCF Intrinsic $1.77 -43.0% $0.37 -80.3%
Earnings Power Value Intrinsic $0.83 -42.4%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $3.90 +25.8% $2.15 +14.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MTVA vs NBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MTVA vs NBP — Which Stock Is More Undervalued?

MTVA scores higher with a 3.7/10 quality rating vs NBP's 3.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MetaVia Inc. (MTVA) and NovaBridge Biosciences (NBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MTVA currently trades at $3.10 with a QOC of 3.7/10, while NBP trades at $1.87 with a QOC of 3.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).